SCHEMBL23496243

SCHEMBL23496243

CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCOC(CC)C(=O)OC(C)(C)C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 2/20 0.48
NR1I2 O75469 2/20 0.48
PTGS2 P35354 2/20 0.48
PGR P06401 1/20 0.48
PDE4D Q08499 1/20 0.48
ALDH1A1 P00352 7/20 0.46
CYP3A4 P08684 2/20 0.46
ALOX15 P16050 2/20 0.46
HSD17B10 Q99714 2/20 0.46
TDP1 Q9NUW8 2/20 0.46
TSHR P16473 1/20 0.46
CYP19A1 P11511 4/20 0.42
F7 P08709 3/20 0.42
F3 P13726 3/20 0.42
PPARG P37231 3/20 0.42
OXER1 Q8TDS5 3/20 0.42
PTGS1 P23219 2/20 0.42
KMT2A Q03164 2/20 0.42
PPARD Q03181 2/20 0.42
PPARA Q07869 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20574219 1.00 ADORA3 (0.48) ADORA3NR1I2PTGS2PGRPDE4D
SCHEMBL290120 0.96 ALDH1A1 (0.45) ADORA3NR1I2PTGS2PGRPDE4D
SCHEMBL290119 0.96 ALDH1A1 (0.45) ADORA3NR1I2PTGS2PGRPDE4D
SCHEMBL21052552 0.95 ALDH1A1 (0.47) ADORA3NR1I2PTGS2PGRPDE4D
SCHEMBL23496246 0.95 ALDH1A1 (0.47) ADORA3NR1I2PTGS2PGRPDE4D
SCHEMBL21052383 0.92 ADORA3 (0.40) ADORA3NR1I2PTGS2PGRPDE4D
SCHEMBL3708103 0.92 ADORA3 (0.40) ADORA3NR1I2PTGS2PGRPDE4D
SCHEMBL3708101 0.92 ADORA3 (0.40) ADORA3NR1I2PTGS2PGRPDE4D
SCHEMBL21052407 0.91 ALDH1A1 (0.41) ADORA3NR1I2PTGS2PGRPDE4D
SCHEMBL21052406 0.91 ALDH1A1 (0.41) ADORA3NR1I2PTGS2PGRPDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12440466-B2 Fatty acid derivatives for treating non-alcoholic steatohepatitis BASF AS (NO) 2025-10-14 US disclosed
EP-3720431-B1 FATTY ACID DERIVATIVES FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS BASF AS (NO) 2024-10-30 EP disclosed
US-20240156769-A1 FATTY ACID DERIVATIVES FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS BASF AS (NO) 2024-05-16 US disclosed
US-11925614-B2 Fatty acid derivatives for treating non-alcoholic steatohepatitis BASF AS (NO) 2024-03-12 US disclosed
US-20210177794-A1 FATTY ACID DERIVATIVES FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS BASF AS (NO) 2021-06-17 US disclosed
CN-111712240-A Fatty acid derivatives for the treatment of non-alcoholic steatohepatitis 巴斯夫股份公司 2020-09-25 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210177794-A1 FATTY ACID DERIVATIVES FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS CPT1A, NR1H3, NR1H2 ADORA3 389/4885NR1I2 155/4885PTGS2 324/4885
US-20240156769-A1 FATTY ACID DERIVATIVES FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS CPT1A, NR1H2, NR1H3 ADORA3 388/4885NR1I2 172/4885PTGS2 343/4885
US-12440466-B2 Fatty acid derivatives for treating non-alcoholic steatohepatitis CPT1A, NR1H2, NR1H3 ADORA3 388/4885NR1I2 172/4885PTGS2 343/4885
US-11925614-B2 Fatty acid derivatives for treating non-alcoholic steatohepatitis CPT1A, NR1H3, NR1H2 ADORA3 389/4885NR1I2 155/4885PTGS2 324/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.